Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cadrenal Therapeutics Inc CVKD

Healthcare Biotechnology
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an... see more

Recent & Breaking News (NDAQ:CVKD)

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Accesswire 7 days ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

PR Newswire August 22, 2024

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

PR Newswire August 20, 2024

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

PR Newswire August 14, 2024

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

PR Newswire August 7, 2024

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

PR Newswire August 6, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

PR Newswire July 17, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

PR Newswire June 11, 2024

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

PR Newswire June 3, 2024

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

PR Newswire May 23, 2024

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

PR Newswire May 9, 2024

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

PR Newswire April 11, 2024

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

PR Newswire April 9, 2024

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

PR Newswire March 11, 2024

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

PR Newswire February 26, 2024

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

PR Newswire February 8, 2024

Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions

PR Newswire January 31, 2024

Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

PR Newswire January 24, 2024

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

PR Newswire January 4, 2024

Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target

PR Newswire December 19, 2023